Clinical Trial Update: High Dose or High Dose Frequency Study of Alglucosidase Alfa [Phase 4]

View source ↗

Summary

Phase 4 clinical trial evaluating high-dose or high-dose-frequency alglucosidase alfa in Pompe disease completed with results posted in 2011.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pompe Disease

Drugs mentioned

• Myozyme (alglucosidase alfa)

Snippet

Sponsor: Genzyme, a Sanofi Company | Conditions: Pompe Disease, Glycogen Storage Disease Type II (GSD-II) | Phase 4 | Status: COMPLETED | Results posted: 2011-04-22